{"nctId":"NCT03615482","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","startDateStruct":{"date":"2018-09-14","type":"ACTUAL"},"conditions":["Pneumococcal Infections"],"count":1200,"armGroups":[{"label":"Concomitant Vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: V114","Biological: QIV","Biological: Matching Placebo for V114"]},{"label":"Non-concomitant Vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: V114","Biological: QIV","Biological: Matching Placebo for V114"]}],"interventions":[{"name":"V114","otherNames":[]},{"name":"QIV","otherNames":["Quadrivalent influenza vaccine (seasonal inactivated)","Fluarix Quadrivalent (Influenza Vaccine)"]},{"name":"Matching Placebo for V114","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good health. Any underlying chronic illness must be documented to be in stable condition.\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: a) not a woman of childbearing potential (WOCBP) OR b) a WOCBP who agrees to use 1 of the contraceptive methods as defined in the protocol during the treatment period and for at least 6 weeks after the last dose of study intervention.\n\nExclusion Criteria:\n\n* History of invasive pneumococcal disease (IPD, positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years before Visit 1 (Day 1)\n* Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine\n* Known hypersensitivity to any component of influenza vaccines, including egg protein, or following a previous dose of any influenza vaccine.\n* Known or suspected impairment of immunological function\n* Experienced Guillain-Barré syndrome within 6 weeks of receiving a previous influenza vaccination\n* Coagulation disorder contraindicating intramuscular vaccinations.\n* History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n* A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1)\n* Prior administration of any PCV (e.g., Prevnar 13®) or is expected to receive any pneumococcal vaccine during the study outside of the protocol.\n* Prior administration of PNEUMOVAX®23 ≤12 months before Visit 1 (Note: individuals who received PNEUMOVAX®23 \\>12 months prior to Visit 1 are eligible for this study.)\n* Previous receipt of influenza vaccine during the 2018/2019 flu season or expected to receive any influenza vaccine during the study outside of the protocol\n* Received systemic corticosteroids (≥20 mg/day prednisone equivalent) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.\n* Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination (Note: Topical, ophthalmic, intra-articular or soft-tissue \\[e.g., bursa, tendon steroid injections\\], and inhaled/nebulized steroids are permitted).\n* Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease\n* Received a blood transfusion or blood products, including immunoglobulin within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.\n* Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.\n* Is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence as assessed by the study investigator.\n* Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Injection-site Adverse Event","description":"An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Solicited injection-site AEs included injection-site erythema /redness, pain /tenderness, swelling.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"71.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"16.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Systemic Adverse Event","description":"An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Solicited systemic AEs included myalgia/muscle pain, arthralgia/joint pain, headache, and fatigue/tiredness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"30.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"21.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Vaccine-Related Serious Adverse Event","description":"A serious adverse event (SAE) is an AE that results in death, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) Ratio of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA)","description":"Serotype-specific OPA GMTs (estimated) and GMT ratios with 95% confidence intervals (CIs) and 1-sided p-values were calculated using a constrained longitudinal data analysis (cLDA) method utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMT ratios); within-group CIs were not calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140.1","spread":null},{"groupId":"OG001","value":"211.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.9","spread":null},{"groupId":"OG001","value":"147.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"901.3","spread":null},{"groupId":"OG001","value":"1078.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"396.1","spread":null},{"groupId":"OG001","value":"500.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5564.2","spread":null},{"groupId":"OG001","value":"6615.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3904.0","spread":null},{"groupId":"OG001","value":"4436.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3563.2","spread":null},{"groupId":"OG001","value":"4119.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2859.6","spread":null},{"groupId":"OG001","value":"2874.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2024.8","spread":null},{"groupId":"OG001","value":"2228.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3022.8","spread":null},{"groupId":"OG001","value":"3802.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3208.4","spread":null},{"groupId":"OG001","value":"3849.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2523.2","spread":null},{"groupId":"OG001","value":"2473.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2243.4","spread":null},{"groupId":"OG001","value":"2932.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2206.2","spread":null},{"groupId":"OG001","value":"2592.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8142.9","spread":null},{"groupId":"OG001","value":"9807.4","spread":null}]}]}]},{"type":"PRIMARY","title":"GMT of Influenza Strain-Specific Hemagglutination Inhibition","description":"Activity for the 4 strains contained in QIV vaccine was determined using an hemagglutination inhibition (HAI) assay. Serotype-specific HAI GMTs (estimated) and GMT ratios with 95% confidence intervals (CIs) and 1-sided p-values were calculated using a constrained longitudinal data analysis (cLDA) method utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMT ratios); within-group CIs were not calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124.82","spread":null},{"groupId":"OG001","value":"115.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.85","spread":null},{"groupId":"OG001","value":"85.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.53","spread":null},{"groupId":"OG001","value":"36.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.47","spread":null},{"groupId":"OG001","value":"33.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) of Pneumococcal Serotype-specific Immunoglobulin G (IgG)","description":"Serotype-specific IgG GMC ratios (estimated) and GMC ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) method utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMC ratios); within-group CIs were not calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":null},{"groupId":"OG001","value":"5.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null},{"groupId":"OG001","value":"0.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":null},{"groupId":"OG001","value":"1.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.65","spread":null},{"groupId":"OG001","value":"5.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.07","spread":null},{"groupId":"OG001","value":"8.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.11","spread":null},{"groupId":"OG001","value":"9.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.68","spread":null},{"groupId":"OG001","value":"5.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.84","spread":null},{"groupId":"OG001","value":"4.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.30","spread":null},{"groupId":"OG001","value":"9.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.99","spread":null},{"groupId":"OG001","value":"12.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.43","spread":null},{"groupId":"OG001","value":"15.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.68","spread":null},{"groupId":"OG001","value":"9.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":null},{"groupId":"OG001","value":"4.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.68","spread":null},{"groupId":"OG001","value":"6.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.19","spread":null},{"groupId":"OG001","value":"10.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in Pneumococcal Serotype-Specific OPA","description":"Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"20.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"SECONDARY","title":"GMFR in Pneumococcal Serotype-Specific IgG","description":"Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"19.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"10.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With GMFR ≥4 in Pneumococcal Serotype-specific OPA","description":"Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay. GMFR is the geometric mean of fold rise from baseline to postvaccination. The percentage of participants who had ≥ 4-fold rise in GMFR were calculated from baseline to postvaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":null},{"groupId":"OG001","value":"66.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"54.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null},{"groupId":"OG001","value":"63.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"75.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"59.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null},{"groupId":"OG001","value":"53.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"40.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"70.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null},{"groupId":"OG001","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null},{"groupId":"OG001","value":"48.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"67.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"67.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":null},{"groupId":"OG001","value":"44.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With GMFR ≥4 in Pneumococcal Serotype-specific IgG","description":"Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination. The percentage of participants who had ≥ 4-fold rise in GMFR are calculated from baseline to postvaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"60.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null},{"groupId":"OG001","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null},{"groupId":"OG001","value":"57.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":null},{"groupId":"OG001","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":null},{"groupId":"OG001","value":"55.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"43.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"68.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null},{"groupId":"OG001","value":"60.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.7","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"69.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":null},{"groupId":"OG001","value":"53.9","spread":null}]}]}]},{"type":"SECONDARY","title":"GMFR of Influenza Strain-Specific HAI","description":"Activity for the 4 strains contained in QIV vaccine will be determined using an HAI assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Influenza Strain-specific HAI Titer ≥1:40","description":"Activity for the 4 strains contained in QIV vaccine will be determined using an HAI assay. Seroconversion is defined as achieving a 4-fold rise from baseline to postvaccination among participants who are seropositive at baseline (HAI titer ≥ 1:10) or a titer of ≥ 1:40 at postvaccination among participants who are seronegative at baseline (HAI titer \\< 1:10).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"84.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"50.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Seroconvert for Influenza Strain-specific HAI","description":"Activity for the 4 strains contained in QIV vaccine will be determined using an HAI assay. Seroconversion for HAI responses is defined as achieving either 1) a 4-fold rise in influenza strain-specific HAI titer from Baseline to Day 30 among participants who are seropositive at Baseline (HAI titer ≥1:10) or 2) a influenza strain-specific HAI titer of ≥1:40 at Day 30 among participants who are seronegative at Baseline (HAI titer \\<1:10).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":null},{"groupId":"OG001","value":"48.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"25.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"28.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"30.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":600},"commonTop":["Injection site pain","Fatigue","Headache","Myalgia","Injection site swelling"]}}}